I like that:
- Dimerix won't even need to muck around with the time and cost of marketing and dealing with the regulatory maintenance etc...
- Dimerix use Neuren (ASX: Neu) as a case study where it went from a $220M market cap at the beginning of Phase 3 to a market cap of $1.6B after first FDA approval with a few milestones catalysts on the way. To me it says DXB see a realistic analogy to its own journey.
Ann: Investor Presentation, page-12
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
56.0¢ |
Change
0.035(6.67%) |
Mkt cap ! $308.1M | |||
| Open | High | Low | Value | Volume |
| 51.5¢ | 57.3¢ | 50.5¢ | $2.179M | 3.991M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 30558 | 56.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 56.5¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |